000285917 001__ 285917
000285917 005__ 20260407160731.0
000285917 0247_ $$2doi$$a10.3389/fimmu.2025.1678840
000285917 0247_ $$2pmid$$apmid:41929475
000285917 0247_ $$2pmc$$apmc:PMC13038563
000285917 037__ $$aDZNE-2026-00363
000285917 041__ $$aEnglish
000285917 082__ $$a610
000285917 1001_ $$aPietrock, Charlotte$$b0
000285917 245__ $$aNeuronal autoantibodies associated with poorer neuropsychological and motor outcomes 6 months after stroke: results from the PHYS-STROKE trial.
000285917 260__ $$aLausanne$$bFrontiers Media$$c2026
000285917 3367_ $$2DRIVER$$aarticle
000285917 3367_ $$2DataCite$$aOutput Types/Journal article
000285917 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1775570666_6266
000285917 3367_ $$2BibTeX$$aARTICLE
000285917 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285917 3367_ $$00$$2EndNote$$aJournal Article
000285917 500__ $$aTrial registration: clinicaltrials.gov NCT01953549
000285917 520__ $$aEmerging evidence suggests a role of neuronal autoantibodies (nAbs) for long-term stroke outcomes. However, data remain limited and many domains unexamined. We present a comprehensive analysis of nAbs and their association with a broad range of outcome measures at multiple timepoints in the six months following moderate stroke.In this explorative analysis of the multicenter, randomized-controlled PHYS-STROKE trial, serum samples from stroke patients were tested for 40 nAbs at baseline (5-45 days post-stroke), post-intervention (4 weeks after baseline), and at three and six months after stroke. Generalized estimating equation (GEE)-models were used to evaluate the dynamics of nAbs over time. Multiple linear regression models were applied to investigate the prognostic role of nAbs on various outcomes at three and six months.Two hundred stroke patients (41% female; mean age: 69 ± 12 years, median acute National Institutes of Health Stroke Scale: 8) were enrolled. Cell-based seroreactivity decreased from baseline to six months (39 of 183 patients [21%] vs. 18 of 137 patients [13%]). while tissue-based reactivity increased (4 of 183 patients [2%] vs. 9 of 137 patients [7%]). The GEE applied to the imputed dataset indicated a statistically significant decreased likelihood of seroreactive nAbs in cell-based assays from baseline to six months (95%CI = 0.36 to 0.98; p = 0.041), while tissue-based analyses showed an inverse effect for the same time period (95%CI = 1.11 to 8.51; p = 0.032). The most frequently detected antibody was anti-N-Methyl-D-Aspartate receptor GluN1 (NMDAR (IgM, IgA, IgG), 30 patients [15.1%]). Baseline nAB seropositivity was associated with worse depression scores (95%CI = 0.03 to 7.82; p = 0.048) and poorer subjective mobility (95%CI=0.04 to 0.99; p = 0.033) at six months post-stroke. NMDAR-antibodies at baseline were linked to a lower subjective overall health rating (95%CI = -17.96 to -0.16; p = 0.046) and lower maximum walking speed (95%CI = -0.57 to -0.03; p = 0.027) at six months. No associations were found with outcomes at three months.Antibody seropositivity was associated with poorer outcomes in certain neuropsychological and motor outcome measures at six but not three months post-stroke. These findings require confirmation in larger cohorts and emphasize the need for future studies with longer follow-up periods in this patient population.clinicaltrials.gov NCT01953549.
000285917 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285917 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285917 650_7 $$2Other$$aNMDAR
000285917 650_7 $$2Other$$abiomarker
000285917 650_7 $$2Other$$aneuroimmunology
000285917 650_7 $$2Other$$aneuronal autoantibodies
000285917 650_7 $$2Other$$aoutcome
000285917 650_7 $$2Other$$arecovery
000285917 650_7 $$2Other$$astroke
000285917 650_7 $$2NLM Chemicals$$aAutoantibodies
000285917 650_7 $$2NLM Chemicals$$aBiomarkers
000285917 650_2 $$2MeSH$$aHumans
000285917 650_2 $$2MeSH$$aAutoantibodies: blood
000285917 650_2 $$2MeSH$$aAutoantibodies: immunology
000285917 650_2 $$2MeSH$$aFemale
000285917 650_2 $$2MeSH$$aMale
000285917 650_2 $$2MeSH$$aAged
000285917 650_2 $$2MeSH$$aStroke: immunology
000285917 650_2 $$2MeSH$$aStroke: blood
000285917 650_2 $$2MeSH$$aStroke: psychology
000285917 650_2 $$2MeSH$$aMiddle Aged
000285917 650_2 $$2MeSH$$aNeurons: immunology
000285917 650_2 $$2MeSH$$aAged, 80 and over
000285917 650_2 $$2MeSH$$aPrognosis
000285917 650_2 $$2MeSH$$aNeuropsychological Tests
000285917 650_2 $$2MeSH$$aBiomarkers: blood
000285917 7001_ $$aNeumann, Konrad$$b1
000285917 7001_ $$aRentzsch, Kristin$$b2
000285917 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b3$$udzne
000285917 7001_ $$aMeisel, Andreas$$b4
000285917 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b5$$udzne
000285917 7001_ $$aNave, Alexander Heinrich$$b6
000285917 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2025.1678840$$gVol. 16, p. 1678840$$p1678840$$tFrontiers in immunology$$v16$$x1664-3224$$y2026
000285917 8564_ $$uhttps://pub.dzne.de/record/285917/files/DZNE-2026-00363.pdf$$yRestricted
000285917 8564_ $$uhttps://pub.dzne.de/record/285917/files/DZNE-2026-00363.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285917 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285917 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285917 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285917 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000285917 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000285917 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000285917 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-12-29T15:23:07Z
000285917 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000285917 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000285917 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000285917 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x1
000285917 980__ $$ajournal
000285917 980__ $$aEDITORS
000285917 980__ $$aVDBINPRINT
000285917 980__ $$aI:(DE-2719)1810003
000285917 980__ $$aI:(DE-2719)1811005
000285917 980__ $$aUNRESTRICTED